Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
BIOLOGICAL

Immunoglobulin

Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.

Trial Locations (4)

2100

NOT_YET_RECRUITING

Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen

5000

NOT_YET_RECRUITING

Department of Neurology, Odense University Hospital, Odense

8000

RECRUITING

Department of Neurology, Aarhus University Hospital, Aarhus C

9000

NOT_YET_RECRUITING

Department of Neurology, Aalborg University Hospital, Aalborg

All Listed Sponsors
collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Aarhus University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Aalborg University Hospital

OTHER

lead

University of Aarhus

OTHER